Ibrahim Turkoz, PhD

Evaluation of Major Treatment Failures in Patients With Recent-Onset Schizophrenia: A Post Hoc Analysis From the Disease Recovery Evaluation and Modification (DREaM) Study

BACKGROUND: Major treatment failures (MTF), such as psychiatric hospitalization and arrest/incarceration, are associated with substantial economic and societal burden, especially for pers...

Amy O'Donnell , MD, JD, BS;

Ibrahim Turkoz , PhD;

Brianne Brown , PsyD;

Pamela Baker , PharmD;

Larry Alphs , MD, PhD;

10/08/2020

Response Rates of Esketamine Nasal Spray Plus an Oral Antidepressant Among Patients Not Meeting Study Criteria for Early Response to Treatment

Objective: Esketamine nasal spray (ESK) plus a newly initiated antidepressant (AD) reduces depression symptoms in patients with treatment-resistant depression (TRD), in a subset meeting s...

Samuel Wilkinson , MD, PhD;

Craig Nelson , MD;

Giacomo Salvadore , MD;

Ibrahim Turkoz , PhD;

Ella Daly , MB, BCh, BAO;

Jaskaran Singh , MD;

David Williamson , PhD, MBA;

Abigail Nash , MD, PhD;

Xiwu Lin , PhD;

Yevgen Tymofyeyev , PhD;

11/22/2019

Impact of Individual and Class of Concomitant Oral Antidepressant on the Efficacy and Safety of Esketamine Nasal Spray in Patients With Treatment Resistant Depression

Objective: Phase 3 trials have demonstrated the efficacy and safety of esketamine nasal spray (ESK) plus a newly initiated oral antidepressant (AD) for treatment-resistant depression (TRD...

Ibrahim Turkoz , PhD;

Jennifer Kern Sliwa , PharmD, BCPP;

Ella Daly , MB, BCh, BAO;

Jaskaran Singh , MD;

Stephane Borentain , MD;

Muideen Adigun , PharmD;

11/22/2019

Impact of Treatment With Esketamine Nasal Spray in Patients With Treatment Resistant Depression and Comorbid Anxiety: A Post-hoc Pooled Analysis of the TRANSFORM 1 and 2 Trials

Purpose: To evaluate the impact of esketamine (ESK) nasal spray in patients with treatment-resistant depression (TRD) and comorbid anxiety.

Ibrahim Turkoz , PhD;

Ella Daly , MB, BCh, BAO;

Stephane Borentain , MD;

Madhukar Trivedi , MD;

Michael Thase , MD;

Jaskaran Singh , MD;

Giacomo Salvadore , MD;

Maggie Fedgchin , PharmD;

H. Lynn Starr , MD, FAAP;

A. John Rush , MD;

11/22/2019

Defining “Adequately Treated”: Characteristics of Patients With Schizophrenia Successfully Transitioned From Paliperidone Palmitate Once Monthly to Paliperidone Palmitate Once-Every-3-Months

Objective: To identify patient characteristics associated with successful transition to once-every-3-months paliperidone palmitate (PP3M).

Edward S. Kim , MD, FACP, MBA;

Amy O'Donnell , MD, JD, BS;

Sanjai Rao , MD;

Ibrahim Turkoz , PhD;

Srihari Gopal , MD;

11/22/2019

Predictors of Response and Remission in Patients With Treatment-Resistant Depression Treated With Esketamine

Objective: Identify patient and disease characteristics associated with greater likelihood of achieving response and remission with esketamine nasal spray (ESK) plus a newly initiated ora...

Ibrahim Turkoz , PhD;

Ella Daly , MB, BCh, BAO;

Jaskaran Singh , MD;

David Williamson , PhD, MBA;

Jack Sheehan , PhD, MBA, RPh;

Kristy Tardieu , BSN, MBA;

03/01/2019

Relapse Rates With Paliperidone Palmitate in Adult Patients With Schizophrenia: Results for the 6-Month Formulation From an Open-label Extension Study Compared to Real-world Data for the 1-Month and 3-Month Formulations

Compare efficacy of the three paliperidone palmitate (PP) long-acting injectable formulations for relapse prevention in schizophrenia: Relapse in schizophrenia has pronounced consequences...

Ibrahim Turkoz , PhD;

10/26/2023

Evaluation of Treatment Failure in a Randomized, Open-Label Study of Paliperidone Palmitate Versus Oral Antipsychotics for Recent-Onset Schizophrenia or Schizophreniform Disorder

Background: Despite the availability of effective treatments, outcomes for patients with schizophrenia remain poor. Nonadherence is common early in the disease course, a time when the gre...

Amy O'Donnell , MD, JD, BS;

Ibrahim Turkoz , PhD;

Brianne Brown , PsyD;

Pamela Baker , PharmD;

Larry Alphs , MD, PhD;

10/08/2020